-
Mashup Score: 5
ASTRO 2022 results of the EXTEND trial: a multicenter, randomized phase II trial evaluating the addition of metastasis-directed therapy (MDT) to intermittent hormone therapy for oligometastatic prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke - 2 year(s) ago
Background: Emerging data suggest tissue within the infarct lesion is not homogenously damaged following ischemic stroke but has a gradient of injury. Using blood-brain-barrier (BBB) disruption as a
Source: StrokeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#STROKE Reduced tissue injury severity — as determined by BBB permeability — mediates the association between reperfusion and favorable outcomes in #LVO patients #EXTEND-IATNK https://t.co/61gyUilulG @Teddyyhwu @vthijs @GeoffreyDonnan @DrBruceCampbell https://t.co/j4nBYlD1qg
-
-
Mashup Score: 0Just a moment... - 4 year(s) ago
This process is automatic. Your browser will redirect to your requested content shortly. Please allow up to 5 seconds…
Source: bit.lyCategories: Cardiologists, Latest HeadlinesTweet-
Excited to announce the publication of our newest #EXTEND @SmithBIDMC work (https://t.co/NBLTGxbabC), led by @MGHHeartHealth @nmbutala @rwyeh evaluating ICD9/10 claims to represent CEC-adjudicated endpoints in the @MDT_Cardiac CoreValve trials. Important foundational work. https://t.co/skckpm2VPf
-
-
Mashup Score: 1QCOR 2020 Science News - 4 year(s) ago
Science News from Quality of Care and Outcomes Research (QCOR) 2020 Scientific Sessions | May, 15-16 2020 | Reston, VA
Source: www.professional.heart.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#EXTEND study findings indicate use of administrative claims to determine outcomes in randomized clinical trials for TAVR is showing promise. https://t.co/saKrDggqXk #QCOR20 Early Career Award Investigator Award semi-finalist. @SmithBIDMC https://t.co/L8TwPqsvNL
-
Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic #ProstateCancer (#EXTEND): A multicenter, randomized phase II trial. Presented by @ChadTangMD @MDAndersonNews. #ASTRO22 written coverage by @rksayyid > https://t.co/Ek0PobMBZh @ASTRO_org https://t.co/ngFcy1LBB5